YSAYPDSVPMMS was shown to bind selectively to the ephrin-A2 receptor, a cell-surface protein present in pathologic angiogenic vasculature, including tumor vasculature, and in many types of cancer cells. Thus, targeting this receptor should allow therapeutic intervention in cancer and other diseases.
M.Koolpe et al., J. Biol. Chem., 277, 46974 (2002)
van Geer MA, Bakker CT, Koizumi N, Mizuguchi H, Wesseling JG, Oude Elferink RP, Bosma PJ. Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J Gastroenterol. 2009 Jun 14;15(22):2754-62.